Provided by Tiger Trade Technology Pte. Ltd.

Loews

107.15
-0.4500-0.42%
Volume:69.17K
Turnover:7.42M
Market Cap:21.90B
PE:13.13
High:108.04
Open:107.34
Low:106.92
Close:107.60
52wk High:121.01
52wk Low:97.38
Shares:204.43M
Float Shares:164.40M
Volume Ratio:0.28
T/O Rate:0.04%
Dividend:0.25
Dividend Rate:0.23%
EPS(TTM):8.16
EPS(LYR):7.97
ROE:9.31%
ROA:1.91%
PB:1.15
PE(LYR):13.44

Loading ...

Insurance Stumbles, But Loews Still Delivers Higher Profit Thanks to Hotels and Energy

Benzinga Earnings
·
Aug 04

Bowhead Specialty Q2 Adjusted EPS Beats Estimates, to be Acquired by American Family

Reuters
·
Aug 03

Loews Q2 2026 Profit Rises as CNA Investment Income and Loews Hotels Earnings Improve

Reuters
·
Aug 03

CNA Financial Q2 Net Income Rises

Reuters
·
Aug 03

CNA Financial Posts Q2 2026 Net Income of $321 Million, or $1.18 a Share

Reuters
·
Aug 03

Earnings Flash (L) Loews Posts Q2 EPS $2.16

MT Newswires Live
·
Aug 03

Loews Q2 FY26 Net Income Rises 14% to $444 Million

Reuters
·
Aug 03

CNA Says Q2 2026 Core Income Slips to $324 Million as Higher Loss Ratio Offsets Investment Income Gain

Reuters
·
Aug 03

Loews Q2 EPS $2.16 Up From $1.87 YoY, Sales $4.734B Up From $4.555B YoY

Benzinga Earnings
·
Aug 03

Loews Q2 Adjusted EPS USD 2.16

THOMSON REUTERS
·
Aug 03

Loews Q2 Net Income Attributable USD 444 Million

THOMSON REUTERS
·
Aug 03

Corrected-Loews Q2 EPS Usd 2.16 (Not 'Adj EPS Usd 2.16')

THOMSON REUTERS
·
Aug 03

U.S. Earnings Preview: Before Market Open Aug. 3

Dow Jones
·
Aug 03

CNA Financial Corp Expected to Post Earnings of $1.08 a Share - Earnings Preview

Reuters
·
Jul 31

AI is making your life more expensive. Here’s how

CNN Business
·
Jul 28

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

GlobeNewswire
·
Jul 27

Earning Preview: Loews revenue momentum steadies while sentiment skews cautious

Earnings Agent
·
Jul 27

Loews (L) Stock Could Be 4% Overvalued As Earnings Look Pricey

Simply Wall St.
·
Jul 25

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

GlobeNewswire
·
Jul 22

Loews Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17